{"nctId":"NCT00087022","briefTitle":"Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer","startDateStruct":{"date":"2004-07"},"conditions":["Kidney Cancer"],"count":864,"armGroups":[{"label":"Arm I","type":"EXPERIMENTAL","interventionNames":["Biological: girentuximab"]},{"label":"Arm II","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]}],"interventions":[{"name":"girentuximab","otherNames":["Rencarex®, cG250 and WX-G250"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed primary clear cell renal cell carcinoma\n\n  * Meets 1 of the following high risk criteria:\n\n    * T3a, N0/NX, M0 OR T3b, N0/NX, M0 OR T3c, N0/NX, M0 OR T4, N0/NX, M0\n    * Any T stage and N + disease and M0\n    * T1b, N0/NX, M0 OR T2, N0/NX, M0, each with grade ≥ 3 (Fuhrman or any other nuclear grading system with at least 3 grades)\n* Prior nephrectomy (total or partial) of primary renal cell carcinoma with documented clear cell histology within the past 12 weeks\n\n  * No evidence of macroscopic or microscopic residual disease\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nPerformance status\n\n* ECOG 0-1\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Platelet count \\> 100,000/mm\\^3\n* WBC \\> 3,000/mm\\^3\n* Hemoglobin \\> 10 g/dL\n\nHepatic\n\n* AST and ALT \\< 3 times upper limit of normal (ULN)\n* Bilirubin \\< 1.5 times ULN\n* Hepatitis B surface antigen (HbsAg) negative\n* Hepatitis C antibody negative\n\nRenal\n\n* Creatinine \\< 2.0 times ULN\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* HIV I and II negative\n* No concurrent unrelated illness which can significantly jeopardize patients' clinical status\n* No active infection\n* No inflammation\n* No medical condition or laboratory abnormalities that would preclude study participation\n* No other malignancies within the past 5 years except surgically cured nonmelanoma skin cancer or carcinoma in situ of the cervix\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* More than 5 years since prior immunotherapy\n* No prior murine or chimeric antibody therapy\n\nChemotherapy\n\n* More than 5 years since prior chemotherapy\n\nEndocrine therapy\n\n* No concurrent corticosteroids above Cushing dose for another disease\n\n  * Physiologic corticosteroid replacement therapy allowed at discretion of the primary investigator\n\nRadiotherapy\n\n* More than 5 years since prior radiotherapy\n\nSurgery\n\n* See Disease Characteristics\n* No prior organ transplantation\n\nOther\n\n* No concurrent immunosuppressive agents (e.g., cyclosporine or tacrolimus)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disease-free Survival","description":"Disease Free Survival (DFS) calculated from the date of randomization up to and including the date of documented relapse as confirmed by the CT, death or start of new anti-tumor therapy.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"197","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival","description":"Overall Survival (OS) calculated from the date of randomization to the date of death. Patients with no documented death will be censored at the date of their last study evaluation.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life - Global Health Status","description":"Quality of life by EORTC Quality of Life Questionnaire-C30 - Global Health Status at 12 months. A high score for the global health status/QoL represents a high QoL with 0 being the minimum and 100 being the maximum.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":"21"},{"groupId":"OG001","value":"71","spread":"20"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics of WX-G250","description":"Quantitative determination of cG250 (Girentuximab) trough serum profiles at week 8 (steady state concentration).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":"5.8"}]}]}]},{"type":"POST_HOC","title":"Disease Free Survival (DFS) for Patients With CAIX Score >= 2.6","description":"This analysis includes patients having a CAIX Expression equal or above the CAIX score of 2.6.\n\nThe CAIX score is determined on the basis of CAIX expression via immunohistochemistry described by a combination of tumor cell extent and staining intensity.\n\nDisease Free Survival (DFS) calculated from the date of randomization up to and including the date of documented relapse as confirmed by the CT, death or start of new anti-tumor therapy.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":431},"commonTop":["HEADACHE","BACK PAIN","FATIGUE","DIARRHOEA","NAUSEA"]}}}